The record
| Class | neuropeptide mixture |
|---|---|
| Also known as | FPF-1070, N-PEP-12, Porcine brain peptide preparation |
| Chain length | - |
| Molecular weight | 10,000 Da |
| Half-life | Variable - complex mixture |
| Route | IV infusion or IM |
| Studied for | Alzheimer's disease (Europe, Asia); Vascular dementia; Stroke recovery; Traumatic brain injury |
| Research use | Neuroprotection studies; Stroke models; Neurodegenerative disease research |
| What has been shown | Neuroprotection against excitotoxicity; Anti-inflammatory (reduces microglial activation); Anti-apoptotic; Promotes neurogenesis and angiogenesis |
| How it works | Complex mixture of 14,635 peptides (<10 kDa) from porcine brain. 25% peptides, 75% free amino acids. Contains fragments of tubulin, actin, myelin basic protein, enkephalins. Multimodal neuroprotective and neurotrophic properties. No intact BDNF/NGF - activity from cryptic peptides. |
| Patent status | proprietary process |
| Regulatory status | approved in 45+ countries (not USA/UK) |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Nerve Support / Neuro-repair Environment (affection, 83%)
- GI Inflammation Modulation (affection, 36%)
- Cognitive Enhancement / Focus (affection, 40%)
- Neuroprotection Signaling (affection, 74%)
- Inflammation Modulation (affection, 38%)
- ADHD (illness, 45%)
- Alzheimer's disease (illness, 100%)
- Cancer immunotherapy adjuvant (illness, 30%)
- Chronic inflammatory conditions (illness, 45%)
- COVID-19 (illness, 30%)
- Diabetic neuropathy (illness, 45%)
- Hepatitis B/C treatment (illness, 30%)
- Neuropathic pain (illness, 45%)
- Sarcoidosis-associated small fiber neuropathy (illness, 45%)
- Sepsis treatment (illness, 30%)
- Stroke recovery (illness, 100%)
- Traumatic brain injury (illness, 100%)
- Vaccine adjuvant (illness, 30%)
- Vascular dementia (illness, 100%)
- Pain (symptom, 50%)
- Low mood (symptom, 67%)
- Memory lapses (symptom, 50%)
- Frequent infections (symptom, 50%)